Compare MRLN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRLN | PLX |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 207.1M |
| IPO Year | 2024 | 1996 |
| Metric | MRLN | PLX |
|---|---|---|
| Price | $0.84 | $2.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.92 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 840.6K |
| Earning Date | 11-15-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $9.23 | $55.77 |
| Revenue Next Year | $153.29 | N/A |
| P/E Ratio | ★ N/A | $9.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $1.65 |
| 52 Week High | $17.00 | $3.19 |
| Indicator | MRLN | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 19.39 | 42.21 |
| Support Level | N/A | $2.21 |
| Resistance Level | $3.45 | $2.75 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 1.68 | 7.41 |
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.